nach oben

Diabetologia

Erschienen in:

01.09.2007 | Editorial

Nice insulins, pity about the evidence

verfasst von: F. Holleman, E. A. M. Gale

Erschienen in: Diabetologia | Ausgabe 9/2007

Einloggen, um Zugang zu erhalten

Excerpt

In February 2006 the German Institute for Quality and Efficiency in Healthcare (IQWiG), an independent body with a mandate to assess the evidence for medical interventions, released its final report on the use of short-acting insulin analogues in the treatment of type 2 diabetes. The report found no advantage over soluble (regular) human insulin. Given that analogues cost more than soluble insulin, the report concluded that there was no evidence to support their use in patients with type 2 diabetes [1]. A subsequent report concluded that the benefits of short-acting analogues in type 1 diabetes were marginal at best [2], and a report on the long-acting analogues is on its way: many suspect that this will be almost equally negative. …

Institut für Qualität and Wirtschaftlichkeit im Gesundheitswesen. Rapid-acting insulin analogues for the treatment of diabetes mellitus type 2: final report. Available from http://www.iqwig.de/download/A05-04_Final_Report_Rapid-acting_insulin_analogues_for_the_treatment_of_diabetes_mellitus_type_2.pdf, accessed 15 June 2007

Institut für Qualität and Wirtschaftlichkeit im Gesundheitswesen. Kurzwirksame insulinanaloga zur Behandlung des diabetes mellitus typ 1: vorbericht [Rapid-acting insulin analogues for the treatment of diabetes type 1: preliminary report]. Available from http://www.iqwig.de/download/A05-02_Vorbericht_Nutzenbewertung_kurzwirksamer_Insulinanaloga_zur_Behandlung_des_Diabetes_mellitus_Typ_1.pdf, accessed 15 June 2007 [in German]

Verband Forschender Arzneimittelhersteller [German Association of Research-Based Pharmaceutical Companies]. Statistics 2006: the pharmaceutical industry in Germany. Available at http://www.vfa.de/download/SHOW/en/vfa_en/publikationen_en/e_statistics/e_statistics_2006.pdf, accessed 15 June 2007

Grill M (2006) Gib dem Affen Zucker [Give the monkey sugar]. Die Stern, 13 June. Available from http://www.stern.de/wissenschaft/medizin/:Streit-Insulin-Analoga-Der-Selbstbedienungsladen/563128.html?eid=567257, accessed 15 June 2007 [in German]

Bliss M (1983) The discovery of insulin. Paul Harris Publishing, Edinburgh

Somogyi M (1959) Exacerbation of diabetes by excess insulin action. Am J Med 26:169–191PubMedCrossRef

Hagedorn HC, Norman Jensen B, Krarup NB, Wodstrup I (1936) Protamine insulinate. JAMA 106:177–180

Deckert T (2000) H. C. Hagedorn and Danish insulin. Poul Christensen Publishing, Herning, Denmark

Jorpes JE (1943) Recrystallised insulin for diabetic patients with insulin allergy. Arch Intern Med 83:363–371

10.

Brange J (1987) Galenics of insulin. Springer, Berlin

11.

Hall SS (1987) Invisible frontiers. The race to synthesize a human gene. Atlantic Monthly, New York

12.

Richter B, Neises G (2005) ‘Human’ insulin versus animal insulin in people with diabetes mellitus. Cochrane Database of Systematic Reviews, Issue 1. Art. No. CD003816. DOI 10.1002/14651858.CD003816.pub2

13.

Gale EAM (1989) Hypoglycaemia and human insulin. Lancet ii:1264–1266CrossRef

14.

Colagiuri S, Miller JJ, Petocz P (1992) Double-blind crossover comparison of human and porcine insulins in patients reporting lack of hypoglycaemia awareness. Lancet 339(8807):1432–1435PubMedCrossRef

15.

Maran A, Lomas J, Archibald H et al (1993) Double blind clinical and laboratory study of hypoglycaemia with human and porcine insulin in diabetic patients reporting hypoglycaemia unawareness after transferring to human insulin. BMJ 306(6879):167–171PubMedCrossRef

16.

Lean MEJ, Ng LL, Tennison BR (1985) Interval between insulin injection and eating in relation to blood glucose control in adults. BMJ 290:105–108PubMed

17.

Gale EAM for the UK Trial Group (2000) A randomized controlled trial comparing insulin lispro with soluble insulin in patients with type 1 diabetes on intensified insulin therapy. Diabet Med 17:209–214CrossRef

18.

Siebenhofer A, Plank J, Berghold A et al (2004) Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database of Systematic Reviews. Art. No.: CD003287. DOI 10.1002/14651858.CD003287.pub4

19.

Roach P, Trautmann M, Arora V, Sun B, Anderson JH (1999) Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Clin Ther 21:523–534PubMedCrossRef

20.

Raskin P, Hu P, Allen A et al (2005) Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28:260–265PubMedCrossRef

21.

Galloway JA, Hooper SA, Spradlin CT et al (1992) Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care 15:666–692PubMedCrossRef

22.

Jorgensen S, Vaag A, Langkjaer L et al (1989) NovoSol Basal: pharmacokinetics of a novel soluble long-acting insulin analogue. BMJ 299(6696):415–419PubMed

23.

Lepore M, Pampanelli S, Fanelli C et al (2000) Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142–2148PubMedCrossRef

24.

De Vries JH (2006) To: Scholtz HE, Pretorius SG, Wessels DH, Becker RHA (2005) Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 48:1988–1995. Diabetologia 49:1125–1126

25.

Havelund S, Plum A, Ribel U et al (2004) The mechanism of protraction of insulin detemir, a long-acting acylated analog of human insulin. Pharm Res 21:1498–1504PubMedCrossRef

26.

Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P (2006) A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29:1269–1274 (Erratum in: Diabetes Care [2007] 30:1035)PubMedCrossRef

27.

Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B (2006) Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 28:1569–1581PubMedCrossRef

28.

Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49:1711–1721PubMedCrossRef

29.

National Collaborating Centre for Women’s and Children’s Health (2004) Type 1 diabetes: diagnosis and management of type 1 diabetes in children and young people. RCOG, London, pp 49–56

30.

National Institute for Clinical Excellence (2005) Guidance on the use of long-acting insulin analogues for the treatment of diabetes—insulin glargine. Technology Appraisal no. 53. Available at: http://guidance.nice.org.uk/TA53/guidance/pdf/English, accessed 15 June 2007

31.

Gale EAM (2004) The Hawthorne Studies: a fable for our times? Q J Med 97:439–449

32.

Devereaux P, Choi PTL, El Dika S et al (2004) An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods. J Clin Epidemiol 57:1232–1236PubMedCrossRef

33.

Montori VM, Wang YG, Alonso-Coello P, Bhagra S (2006) Systematic evaluation of the quality of randomized controlled trials in diabetes. Diabetes Care 29:1833–1838PubMedCrossRef

34.

Gale EAM (2001) Lessons from the glitazones: a story of drug development. Lancet 357:1870–1875PubMedCrossRef

35.

Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA (2004) Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 47:622–629PubMedCrossRef

36.

Ashwell SG, Amiel SA, Bilous RW et al (2006) Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med 23:285–292PubMedCrossRef

37.

Hauber A, Gale EAM (2006) The market in diabetes. Diabetologia 49:247–252PubMedCrossRef

Titel: Nice insulins, pity about the evidence
verfasst von: F. Holleman
E. A. M. Gale
Publikationsdatum: 01.09.2007
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 9/2007
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-007-0763-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

16.04.2024 | Spondylitis ankylosans | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Nice insulins, pity about the evidence

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2007

School marks for Swedish children whose mothers had diabetes during pregnancy: a population-based study

Mutations in HHEX are not a common cause of monogenic forms of beta cell dysfunction

Insulin resistance and cortisol metabolism. Reply to Kerstens MN, Dullaart RPF [letter]

Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Reply to Lambert GW et al (letter)

Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy

Comment on: Holt HB, Wild SH, Postle AD et al (2007) Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men. Diabetologia 50:1024–1032

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Innere Medizin